3.190USD-2.15%Mkt Cap: 195.00M USDP/E: —Last update: 2026-05-26
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat live…
Industry Peers
Medical Devices151.38BUSDP/E 24.3
119.84BUSDP/E 36.2
86.12BUSDP/E 24.2
53.79BSEKP/E 100.1
52.47BSEKP/E 22.3
51.50BDKKP/E 21.8
50.54BUSDP/E 47.4
38.75BEURP/E 18.3
Indicators:|
Key Statistics
Company
Market Cap195.00M USD
Enterprise Value189.82M USD
Revenue (TTM)44.88M USD
Gross Profit38.19M USD
Net Income (TTM)-39.23M USD
Revenue/Share1.024 USD
Last Price3.190 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees102
CountryUS
SectorHealthcare
IndustryMedical Devices
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-13.80
PEG—
EV/EBITDA-6.92
EV/Revenue4.23
P/S4.72
P/B-5.10
EPS (TTM)-1.42
EPS (Forward)-0.25
52W Range
2.20017% of range7.950
52W High7.950 USD
52W Low2.200 USD
Profitability
Gross Margin84.57%
Oper. Margin-94.52%
EBITDA Margin-61.13%
Profit Margin-86.88%
ROE115.85%
ROA-111.03%
Growth
Revenue Growth-2.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-18.01M USD
CapEx (TTM)918.00K USD
FCF Margin-20.73%
FCF Yield-4.77%
Net Debt-22.07M USD
Net Debt/EBITDA0.80
Balance Sheet
Debt/Equity-1.02
Current Ratio5.78
Quick Ratio5.24
Book Value/Sh-0.6770 USD
Cash/Share0.9210 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)8.800 USD
Target Range7.000 USD – 11.00 USD
# Analysts5
Ownership
Shares Out.61.42M
Float51.54M
Insiders33.91%
Institutions34.44%
Short Interest
Short Ratio10.1d
Short % Float3.10%
Short % Out.2.35%
Shares Short1.44M
Short (prev mo.)1.20M
Technical
SMA 504.080 (-21.8%)
SMA 2004.942 (-35.4%)
Beta0.56
S&P 52W Chg28.31%
Avg Vol (30d)529.45K
Avg Vol (10d)1.33M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—